Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05632315
Other study ID # 852552
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date January 2026

Study information

Verified date April 2024
Source University of Pennsylvania
Contact Brendan J Kelly, MD, MS
Phone (215) 662-6932
Email brendank@pennmedicine.upenn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant bacteria.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date January 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Multidrug-resistant organism (MDRO) infection of the bloodstream, respiratory tract, or urinary tract. Qualifying MDROs include extended-spectrum cephalosporin-resistant Enterobacterales (ESCRE) or carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa resistant to two or more classes of antibiotics (MDR-PA), vancomycin-resistant Enterococcus (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). 2. On appropriate antibiotic treatment per clinical phenotypic susceptibility testing of the qualifying MDRO, and with a qualifying antibiotic class. Qualifying antibiotic classes include beta-lactam + beta-lactamase inhibitor, carbapenem (with or without betalactamase inhibitor), fluoroquinolone, lipopeptide, glycopeptide, or oxazolidinone. 3. Expected duration of inpatient antibiotic treatment for index MDRO infection at least 5 days total. 4. At least two calendar days remaining, and no more than 7 calendar days remaining prior to planned completion of antibiotic treatment for index MDRO infection. 5. Age = 18 years. Exclusion Criteria: 1. Evidence of colon/small bowel perforation at the time of study screening. 2. Unable to tolerate enteral and enema nutrition and medication administration (i.e., only able to tolerate intravenous nutrition and medications). 3. Goals of care are directed to comfort rather than curative measures. 4. Moderate (ANC < 1000 cells/uL) or severe (ANC < 500 cells/uL) neutropenia. 5. Known food allergy that could lead to anaphylaxis. 6. Known allergy to fecal microbiota transplant products or their components 7. Pregnancy or lactation 1. For subjects of childbearing potential (ages 18 to 55) and who are randomized to receive the intervention, the subject must have a negative pregnancy test within 24 hours prior to product administration 2. Female or male subjects (ages 18 to 55) of reproductive potential engaged in active sexual activity that could lead to a pregnancy must agree to use one of the following forms of birth control while receiving study medications and through day 28 following completion of treatment, at minimum: i. Male or female condoms ii. Diaphragm or cervical cap with spermicide, if available iii. Intrauterine device (IUD) iv. Oral contraceptives or other hormonal contraception 8. Known gastrointestinal disease that could affect the safety of fecal microbiota transplant at time of enrollment: 1. Inflammatory Bowel Disease (IBD) 2. Short Gut Syndrome 3. Fistulas 4. Bowel resection surgery 5. Colitis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PMT
Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)

Locations

Country Name City State
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with resolution of index MDRO colonization of the gut measured by selective stool culture, resolution will be defined as the absence of growth of the index MDRO on selective culture media. 30 (+/-7)- day visit after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Primary Frequency of solicited adverse events (AEs) randomization until 180 day visit after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Primary Frequency of serious adverse events (SAEs) randomization until 180 day visit after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Primary Frequency of adverse events of special interest (AESIs) randomization until 180 day visit after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Primary Frequency of medically attended adverse events (MAAEs) randomization until 180 day visit after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Eradication of gut colonization with the index MDRO i.e., negative selective bacterial culture for the index MDRO to be assessed in addition to primary endpoint 7 days and 90 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Eradication of gut colonization with any of the included MDROs 7- , 30-, and 90-days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary All-cause mortality 30- and 60-days following SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Colectomy occurrence within 30 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Cumulative days of hospitalization from randomization to 30 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Cumulative days of intensive care from randomization to 30 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Bacteria growth in blood samples from randomization to 30 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Hospital admission within 60 days of discharge from index hospitalization
Secondary Hospital admission within 180 days after SCAIM (scheduled completion of appropriate antibiotics for the index MDRO infection)
Secondary Instances of worsened abdominal pain, fever, tachycardia, and hypotension randomization until 180-day visit
Secondary Instances of aspiration (including reduced oxygen saturation, tachypnea, or respiratory distress (PMT-002 upper entral delivery only) randomization until 180-day visit
Secondary Instances of fever, diarrhea, nausea and vomiting 7-, 30-, 90- and 180 day follow up visits
Secondary Instances of new metabolic disease, including hyperglycemia, thyroid disease, weight gain or loss 30-, 90- and 180 day follow up visits
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Completed NCT00980980 - Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) N/A
Recruiting NCT03412500 - Vancomycin Dosage Adjustment for MRSA Infections Phase 4
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Terminated NCT01196169 - Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Phase 4
Completed NCT00996112 - Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections N/A
Not yet recruiting NCT00773799 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community N/A
Not yet recruiting NCT00773864 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers N/A
Completed NCT01350479 - Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers N/A
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT01200654 - Population Pharmacokinetics of Linezolid Phase 4
Withdrawn NCT00856089 - Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization Phase 4
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02814916 - Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Phase 3
Withdrawn NCT00713674 - Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx N/A
Completed NCT03886623 - A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients N/A
Not yet recruiting NCT01356472 - Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia Phase 4
Completed NCT01141101 - Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus N/A
Completed NCT01138462 - Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions N/A